Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11616943 | PMC |
| http://dx.doi.org/10.4103/idoj.idoj_699_23 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Gliptin-Associated Bullous Pemphigoid - A Series of 3 Cases.
Indian Dermatol Online J
October 2024
Department of Dermatology, College of Medicine and Sagore Dutta Medical College, Kamarhati, West Bengal, India.
HLA alleles associated to susceptibility to gliptin-associated bullous pemphigoid in Italian patients.
HLA
August 2024
Molecular and Cell Biology Laboratory, Istituto Dermopatico dell'Immacolata (IDI)-IRCCS, Rome, Italy.
Article Synopsis
- Bullous pemphigoid (BP) is a rare autoimmune skin disorder, becoming more frequent with associations noted with certain diabetes medications called gliptins.
- A study analyzed 30 idiopathic bullous pemphigoid (IBP) patients and 86 gliptin-associated BP (GABP) patients to explore genetic risk factors.
- The research found a significant link between the HLA-DQB1*03:01 allele and both IBP and GABP, suggesting genetic markers that could indicate susceptibility to BP, particularly in individuals who have taken gliptins.
Identification of Risk Factors for Gliptin-associated Bullous Pemphigoid among Diabetic Patients.
Acta Derm Venereol
April 2024
Division of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Article Synopsis
- Drug-associated bullous pemphigoid can occur in patients with type 2 diabetes who use gliptins (dipeptidyl-peptidase 4 inhibitors) long-term, prompting a study to identify risk factors.
- The research compared 76 patients who developed bullous pemphigoid after gliptin treatment to 8,060 who did not, and found a significant association with Alzheimer’s disease, dementia, and the concurrent use of thiazide or loop diuretics.
- It concluded that gliptins should be used carefully in diabetic patients with dementia and those on diuretics, recommending sitagliptin over linagliptin and vildagliptin to reduce risk.
[Gliptin-associated bullous pemphigoid: Case report and literature review].
Rev Esp Geriatr Gerontol
April 2023
Servicio de Geriatría, Hospital Universitario Ramón y Cajal, Madrid, España.
Use of gliptins reduces levels of SDF-1/CXCL12 in bullous pemphigoid and type 2 diabetes, but does not increase autoantibodies against BP180 in diabetic patients.
Front Immunol
August 2022
Department of Dermatology, PEDEGO Research Unit, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland.
The use of dipeptidyl peptidase 4 (DPP4) inhibitors, (also known as gliptins), is associated with an increased risk of bullous pemphigoid (BP), an autoimmune blistering skin disease. To explore the mechanism behind gliptin-associated BP we investigated circulating autoantibodies against the major BP autoantigen BP180 in serum samples from patients with type 2 diabetes (T2D) with preceding gliptin medication (n = 136) or without (n = 136). Sitagliptin was the most frequently prescribed gliptin (125/136 patients).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!